Skip to main content

Month: September 2021

Announcement of drawings (CK95) – Nykredit Realkredit A/S

To Nasdaq Copenhagen Announcement of drawings (CK95) Pursuant to s 24 Danish Capital Markets Act, Nykredit Realkredit A/S hereby publishes drawings data as at 24 September 2021. Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on nykredit.com/ir. For further information about data format and contents, please refer to the Nasdaq website. Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21. Yours sincerelyNykredit Realkredit A/SAttachmentsAnnouncement of drawings Nykredit Realkredit A_S – 24-09-2021XML_Udtrækningsmeddelelse – Announcement of drawings – CK95 – Nykredit Realkredit A_S – 24-09-2021

Continue reading

Stellantis and TotalEnergies welcome Mercedes-Benz as a new partner of Automotive Cells Company (ACC) and raise its capacity plan to at least 120 GWh by 2030

Stellantis and TotalEnergies welcome Mercedes-Benz as a new partner of Automotive Cells Company (ACC) and raise its capacity plan to at least 120 GWh by 2030Mercedes-Benz becomes an equal shareholder of ACC along with Stellantis and TotalEnergies, each with 1/3 equity stake Mercedes-Benz to provide technology and production know-how to Automotive Cells Company (ACC). The partners will accelerate ACC’s development with an objective of at least 120 GWh of cell capacity by 2030Paris, 24 September 2021 – Stellantis, TotalEnergies and Mercedes-Benz have entered into agreements to welcome Mercedes-Benz as a new partner of Automotive Cells Company (ACC). Following its entry, the partners commit to increase ACC’s industrial capacity to at least 120 GWh by 2030. The transaction is subject to agreement on definitive documentation and customary...

Continue reading

PGS Awarded Contract Offshore Suriname

September 24, 2021: Oslo, Norway, PGS has secured a 3D acquisition contract by ExxonMobil for work offshore Suriname. Ramform Tethys is scheduled to commence acquisition during Q4 2021, and it is planned to complete in Q1 2022. “We are very pleased with this contract award by ExxonMobil. We are increasingly familiar with Caribbean waters and have proven the productivity advantage of our Ramform Titan-class acquisition platform and superior data quality provided by our multi–sensor GeoStreamer technology in this prolific exploration area,” says President & CEO in PGS, Rune Olav Pedersen.FOR DETAILS PGS, CONTACT:Bård Stenberg, VP IR & Corporate Communication Mobile: +47 99 24 52 35PGS ASA and its subsidiaries (“PGS” or “the Company”) is an integrated marine geophysics company, which operates world-wide. The Company...

Continue reading

Cardiovascular Drugs Market Size is Projected to Reach USD 63.96 Billion at CAGR to 3.8% by 2026

Cardiovascular Drugs Market Key Players Studied in this Report are Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca, Sanofi, Novartis AG, Merck & Co., Inc., Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd and other key market players. Pune, India, Sept. 24, 2021 (GLOBE NEWSWIRE) — According to the report, Cardiovascular Drugs Market size is projected to reach USD 63.96 billion at CAGR to 3.8% by 2026. The increasing demand for effective drugs and therapy is expected to aid the growth of the market.  The rising R&D investment for innovative drugs and cardiovascular therapeutics will further accelerate the growth of the market. The launch of novel therapies by key players is likely to create growth opportunities for the market. For instance, Novartis AG and Blackstone’s Life...

Continue reading

Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders

New data show pre-symptomatic babies with spinal muscular atrophy (SMA) treated with Evrysdi maintained the ability to swallow Evrysdi has demonstrated consistent clinically meaningful efficacy in adults, children, and babies two months and older and is now approved in 58 countries worldwide Further presentations included data from studies supporting the efficacy, safety, and durability of gene therapy, SRP-9001, in the treatment of Duchenne muscular dystrophy (DMD)Basel, 24 September 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from across its growing neuromuscular portfolio at the World Muscle Society (WMS) Virtual Congress 20 – 24 September 2021. The presentations included additional results from the RAINBOWFISH study, evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic...

Continue reading

AKWEL: NET EARNINGS OF €38 M IN H1 2021

        Thursday 23 September 2021 NET EARNINGS OF €38 M IN THE H1 OF 2021 AKWEL (FR0000053027, AKW, PEA-eligible), the automotive and HGV equipment and systems manufacturer specialising in fluid management and mechanisms, published its 2021 half-yearly results.Consolidated data – in € millions 30.06.2021 30.06.2020 Var. in %Revenue 487.6 387.0 +26.0%EBITDA 64.7 60.0 +7.9%Current operating income 50.0 24.3 +105.8%Current operating margin 10.3% 6.3% +4.0 ptsOperating income 50.7 25.3 +100.9%Financial income (0.6) (1.0) -36.8%Net result (group share) 38.0 20.2 +88.1%Net margin 7.8% 5.2% +2.6 ptsIn the first half of 2021, AKWEL recorded consolidated revenue of €487.6 m, up 26.0% on 2020 and 33.7% at a constant scope and exchange rates, but it is still down nearly 14% compared to the same period of 2019....

Continue reading

Questerre files application for carbon storage reservoir test

THIS NEWS RELEASE IS NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OF AMERICA TO UNITED STATES NEWSWIRE SERVICES OR UNITED STATES PERSONS CALGARY, Alberta, Sept. 24, 2021 (GLOBE NEWSWIRE) — Questerre Energy Corporation (“Questerre” or the “Company”) (TSX,OSE:QEC) reported it has filed an application with the Ministry of Energy and Natural Resource in Quebec to test a reservoir for carbon storage potential. The operation will consist primarily of an injectivity test to gather data on both the safe rate of injection and storage potential. The Company identified the storage formation earlier this year after studying its proprietary seismic and well data. The Company holds the exclusive right to explore for storage reservoirs over one million acres in Quebec. Plans are underway for a 2-D and 3-D seismic survey over areas...

Continue reading

Dentsply Sirona announces a comprehensive restage of its Implant business

With a digital base, historical product strength and signature workflows supported by ongoing education and training, Dentsply Sirona is launching DS Implants, harmonizing successful brands like Simplant, OSSIX, Atlantis and MIS. Three completely connected, seamless signature workflows will take full advantage of digital dentistry for excellent outcomes and patient satisfaction. DS Implants presents DS PrimeTaper, a self-tapping implant with a tapered design that can be inserted safely and easily with a unique double thread, enabling long-term bone stability.CHARLOTTE, N.C., Sept. 23, 2021 (GLOBE NEWSWIRE) — DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY) introduces a comprehensive restage of its Implants business, including three signature workflows to provide dental professionals with a completely new way of practicing...

Continue reading

Immuron Director resignation

MELBOURNE, Australia, Sept. 24, 2021 (GLOBE NEWSWIRE) — Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today received the resignation of Mr Peter Anastasiou. Mr Anastasiou joined the Board in May 2015 after becoming a major shareholder in 2013 and was appointed Vice Executive Chairman in August 2015 to assist US market development opportunities and supporting key programs at Immuron. Mr Anastasiou commented that “Small companies rarely get an opportunity to acquire a transformative asset of national significance. Our shareholders have lost a chance to contribute to the advancement of very safe Covid vaccine. As a result, I have decided to step down despite my confidence...

Continue reading

CVB Financial Corp. Announces Termination of its 10b5-1 Stock Repurchase Program

ONTARIO, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) — CVB Financial Corp. (NASDAQ: CVBF) (the “Company”) announced today that effective immediately it has terminated its 10b5-1 stock repurchase program in order to comply with Regulation M under the Securities Exchange Act of 1934, as amended. The termination is related to the announced acquisition by the Company and its principal subsidiary, Citizens Business Bank, of Suncrest Bank. Suncrest Bank will be engaged in a proxy solicitation associated with the prospective issuance of the Company’s common stock in connection with the Agreement and Plan of Reorganization and Merger among the Company, its principal subsidiary, Citizens Business Bank and Suncrest Bank, dated July 27, 2021, which in turn caused Regulation M to become applicable to any repurchases by the Company of its common...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.